JCR Pharmaceuticals (OTCMKTS:JCRRF – Get Free Report) is expected to be issuing its resultson Thursday, July 30th. Analysts expect JCR Pharmaceuticals to announce earnings of ($0.0693) per share and revenue of $61.28 million for the quarter.
JCR Pharmaceuticals Stock Performance
Shares of JCRRF opened at $3.31 on Tuesday. JCR Pharmaceuticals has a 1-year low of $3.15 and a 1-year high of $3.31. The company has a 50-day moving average of $3.39 and a 200 day moving average of $3.96.
JCR Pharmaceuticals Company Profile
JCR Pharmaceuticals Co, Ltd. is a Japan-based biotechnology company specializing in the development, production and commercialization of plasma-derived products and regenerative medicine solutions. The company focuses on manufacturing high-purity plasma proteins, including human serum albumin, immunoglobulins and coagulation factors, to support a range of therapeutic applications in hematology, immunology and critical care settings.
In its plasma-derived business, JCR leverages state-of-the-art fractionation and purification processes to supply products such as intravenous immunoglobulin and albumin formulations.
Featured Articles
- Five stocks we like better than JCR Pharmaceuticals
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for JCR Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JCR Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
